BeOne has gained exclusive rights to develop and commercialize four Revolution candidates in certain Asian markets.

PMC's new president and CEO said the organization is expanding beyond oncology, engaging with Capitol Hill, and challenging a controversial research grant rule.

Phase I/II SONIX trial will enroll 10 children with biallelic GJB2 variants to evaluate the gene therapy, called SKY-GJB2.

The investigator-initiated trial comes after Elicio said a Phase II trial of ELI-002 7P in adjuvant pancreatic cancer did not meet its primary endpoint.

The deal centers on Actio's small molecule for KCNT1-related epilepsy. Meanwhile, Actio will spin out a separate company with its other assets.

The PGDx elio tissue complete CDx can be used to detect BRAF V600E or V600K mutations and select patients for targeted therapies.

If the FDA approves lonvo-z, Intellia expects it will be able to launch the drug, its first commercial product, in the first ...

The firm disclosed the update on the gene therapy, which it acquired in its 2021 purchase of Prevail Therapeutics, in its Q2 ...

NEW YORK – Rocket Pharmaceuticals is discussing next steps to complete a pivotal Phase II trial of its Danon disease gene therapy, RP-A501, with the US Food and Drug Administration based on promising ...

Overall, the firm's sales were up 10 percent and beat Wall Street expectations, but net income took a hit from recent ...

The network of community oncology practices eventually hopes to integrate the tool with its genomic databases.

The firm's personalized immunotherapy DISP-10 combines an engineered tumor-specific virus with BMS's CAR T-cell therapy Abecma.